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ABSTRACT
Protein aggregation is a hallmark of a growing num-
ber of human disorders and constitutes a major bot-
tleneck in the manufacturing of therapeutic proteins.
Therefore, there is a strong need of in-silico meth-
ods that can anticipate the aggregative properties of
protein variants linked to disease and assist the engi-
neering of soluble protein-based drugs. A few years
ago, we developed a method for structure-based
prediction of aggregation properties that takes into
account the dynamic fluctuations of proteins. The
method has been made available as the Aggrescan3D
(A3D) web server and applied in numerous studies of
protein structure-aggregation relationship. Here, we
present a major update of the A3D web server to
version 2.0. The new features include: extension of
dynamic calculations to significantly larger and mul-
timeric proteins, simultaneous prediction of changes
in protein solubility and stability upon mutation,
rapid screening for functional protein variants with
improved solubility, a REST-ful service to incorpo-
rate A3D calculations in automatic pipelines, and a
new, enhanced web server interface. A3D 2.0 is freely
available at: http://biocomp.chem.uw.edu.pl/A3D2/
INTRODUCTION
Protein aggregation lies behind more than 40 human dis-
eases, ranging from neurodegenerative disorders to some
types of cancers or diabetes type II (1,2). In addition, aggre-
gation is a major limitation in the production, storage and
administration of life-saving protein pharmaceuticals, like
antibodies and replacement enzymes, since it both reduces
the percentage of therapeutically active molecules and in-
creases immunogenic responses (3).
The growing concern about protein aggregation has fu-
eled the development of over twenty predictive algorithms
(4,5). A majority of methods identify and score protein ag-
gregation prone regions (APRs) relying only on protein se-
quence. Those programs find difficulties predicting APRs
of folded globular proteins, failing to detect APRs when
residues are not contiguous in sequence or mistaking APRs
for the buried hydrophobic core. These problems motivated
the development of a second generation of algorithms that
use structure-based approaches for their predictions (6). In
2015, we developed the Aggrescan3D (A3D) web server for
prediction of aggregation properties of protein structures
(7). The A3D method was shown to outperform sequence-
and composition-based algorithms when dealing with pro-
teins in their native-like states (7,8).
A3D integrates the 3D information of protein structures
and evaluates the contribution of solvent-exposed APRs.
The method works by projecting experimental aggregation
propensities onto a protein structure. Aggregation propen-
sity is calculated for spherical regions centred on every
residue alpha-carbon using the intrinsic amino acid aggre-
gation scale from the Aggrescan method (9,10), the first
sequence-based algorithm to exploit empirical in vivo data.
This provides a structurally corrected aggregation value
(A3D score) for each particular amino acid, depending on
its specific conformational context, discarding the negligi-
ble contribution of hydrophobic residues buried in the core
of folded proteins and focusing on protein surfaces. The dy-
namic structural fluctuations of proteins in solution influ-
ences the degree of exposure of APRs. For this reason, A3D
incorporates the CABS-flex approach (11,12) for fast simu-
lations of protein flexibility in its dynamic mode. Moreover,
A3D allows the introduction of user-defined mutations to
rationally design more soluble protein variants or to test
the impact of disease-linked mutations on the aggregation
propensity.
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Among other applications, A3D has been exploited to
understand the binding of chaperones to their targets (13),
to study the binding of antimicrobial proteins to mem-
branes (14), to rationalize the yield of engineered nanobod-
ies (15), to study the aggregation properties of pathogenic
(16,17) and non-pathogenic (18) globular proteins or to
assist the design of biotechnologically relevant proteins
(19,20).
In this work, we present a major update of the original
A3D, which significantly extends its capabilities. A3D 2.0
incorporates three major feature upgrades.
• protein flexibility simulations using new CABS-flex stan-
dalone package (21), which extends the dynamic mode
analysis range to proteins up to 4000 residues long and
consisting of up to 10 chains.
• protein stability calculations using the FoldX force field
(22), allowing to account for the impact of amino acid
substitutions on the overall structure stability.
• an ‘automated mutations’ tool that identifies high scoring
residues in structural APRs and suggests protein variants
with optimized solubility.
These features were implemented to address the major
A3D drawbacks according to users’ feedback. (i) Protein
size limitations in the dynamic mode, restricted only to
single-chain proteins shorter than 400 amino acids; (ii) the
user-introduced mutations might impact negatively protein
stability, resulting in unfolding and increased aggregation;
(iii) the design of improved solubility variants required sig-
nificant knowledge about the structural and aggregational
determinants of proteins and, thus, was not accessible to
many potential users.
Additionally, A3D 2.0 incorporates an updated REST-
full service that allows the user to incorporate its calcula-
tions in automatic pipelines and a newly designed interface




The original A3D server was described in detail elsewhere
(7). A3D server can be run in Static Mode (default) or Dy-
namic Mode. The static mode was validated by predicting
the solubility of a large set of protein mutational variants,
whereas the dynamic mode allowed to uncover disease rel-
evant APRs not identified by alternative approaches (7,8).
The key principles of A3D 2.0 remain similar to these of the
original web server and here we only detail major method-
ological modifications. The overview of the method pipeline
is presented in Figure 1.
Calculation of the impact of introduced mutations on protein
thermodynamic stability
Users can introduce individual or multiple mutations before
or after running A3D 2.0. The selected mutations are mod-
eled on top of the protein structure using FoldX (22) and
the predicted change in stability, relative to the reference
molecule, is calculated. Positive and negative values indicate
Figure 1. The pipeline of Aggrescan3D 2.0 server.
decreased and increased stabilities upon mutation, respec-
tively.
Automated mutation workflow
The input structure is optimized using FoldX (22) and
the most aggregation-prone residues identified according to
their A3D score. These residues are individually mutated
to solubilizing charged amino acids (arginine, aspartic acid,
glutamic acid and lysine), excluding those positions speci-
fied by the user. The changes in aggregation propensity and
stability are calculated for each potential point mutant and
short-listed according to these values, up to a maximum of
12 suggested changes. Only the two most solubilizing mu-
tations for each particular position are shown, in order to
maximize the number of positions that can be potentially
engineered (up to 6).
NEW FEATURES AND UPDATES
Analysis of the impact of protein flexibility in the aggregation
properties of large and multimeric proteins
In its dynamic mode, A3D was able to capture the influ-
ence of structural flexibility on protein aggregation by in-
corporating the CABS-flex protocol, an efficient alternative
to classical all-atom Molecular Dynamics (11,12,21,23,24).
A set of protein models (in an all-atom resolution) reflect-
ing the most dominant structural fluctuations in the near-
native ensemble are generated with CABS-flex for each
input structure. Then, the highest A3D scoring model is
selected as a proxy of the most aggregation-prone con-
former in solution. Although this feature uncovered struc-
tural APRs not accessible to other structure-based predic-
tors (7), its use was restricted to relatively small, single chain
proteins, which impeded the analysis of many biomedical
and biotechnologically important proteins. With A3D 2.0
we extended the dynamic mode to larger and multimeric
proteins by dedicating significantly larger computational re-
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We used A3D 2.0 to analyse the influence of protein dy-
namics on the aggregation properties of multimeric pro-
teins, using a data set of 163 proteins (69 homodimers, 54
heterodimers and 60 antibodies) (Supplementary Table S1).
In the dynamic mode, A3D 2.0 rendered 12 models for each
input structure and calculated their individual A3D scores.
Afterward, these values were compared with the ones ob-
tained for the same proteins ran in static mode. We found
the input static structures to be the least aggregation-prone
in a large majority of cases, both for the complete set and
when the three protein categories were analyzed separately
(Figure 2A). We averaged the A3D scores of the 12 models
for each individual protein as a proxy for the aggregation
propensity of its native-like ensemble. The resulting aver-
age value was higher than that of the static structure in 80%
of the cases (Supplementary Table S1). These results have
important implications, since most alternative structure-
based aggregation predictors work directly on PDB struc-
tures and, therefore, they might underscore the aggregation
of multimeric proteins by ignoring the contribution of tran-
siently exposed APRs. This effect is illustrated in Figure 2B
for bevacizumab, a humanized monoclonal antibody pre-
scribed for the treatment of different types of cancers (25).
The Fab domain of bevacizumab is very aggregation-prone,
and, accordingly, the antibody must be formulated at low
concentrations (26,27). The comparative static and dynamic
analysis of bevacizumab Fab fragment (two chains, four do-
mains) suggests that structural fluctuations result in an in-
creased aggregation-prone area, with newly exposed APRs
ready to establish intermolecular interactions. The same ef-
fect was observed for other therapeutic antibodies, replace-
ment enzymes like -galactosidase or pharmaceutically im-
portant targets such as insulin and androgen receptors.
Simultaneous analysis of the impact of user-selected muta-
tions in protein solubility and stability
The A3D server allowed users to mutate one or more se-
lected residues in the structure, pre- or post-analysis, in or-
der to evaluate the impact in protein aggregation. How-
ever, these mutations might also affect the protein thermo-
dynamic stability, an effect that was not taken into account
at that time. Indeed, we have shown that there exists a strict
correlation between the destabilizing impact of a given mu-
tation and the increase it promotes in protein aggregation
(28,29). Thus, the solubilizing impact of a residue substitu-
tion can be completely cancelled if it impacts the protein
stability.
Mutations at the protein surface are generally better tol-
erated that residue changes in the protein interior (30).
However, when we used A3D to identify the top solubi-
lizing point mutations for a set of 75 globular proteins, it
turned out that 10% of these superficial changes (32/324)
destabilized the protein >1 kcal/mol according to FoldX
(Supplementary Table S2). This motivated us to introduce
a simultaneous prediction of protein solubility and stabil-
ity changes upon mutation in A3D 2.0, to identify muta-
tions that decrease globular proteins aggregation propen-
sities without compromising their stability and function.
This approach was exploited to design of a fast-folding,
aggregation-resistant GFP variant (19) (Figure 3). The
analysis of the original GFP structure with A3D 2.0, indi-
cated the existence of three hydrophobic residues exposed at
the protein surface, whose mutation to either K or D would
be equally solubilizing. However, the energetic analysis indi-
cated that mutations to K would be neutral, whereas muta-
tions to D would destabilize the protein. Two GFP variants
in which the three hydrophobic residues were changed either
to K or D were recombinantly expressed. As predicted, the
triple K GFP mutant (GFP/KKK) was highly soluble, pre-
served the native structure and was fully functional, whereas
the triple D variant (GFP/DDD) was inactive and could
not be purified. Importantly, the behavior of GFP/KKK
and GFP/DDD designs, could not be anticipated by any
other alternative sequence- or structure-based algorithm.
A3D 2.0 advises now against the experimental characteri-
zation of destabilized re-designs (G > 1 kcal/mol), irre-
spective of their A3D scores. G values are provided in
the ‘Project details’ tab.
Automated design of solubility improved protein variants
The search for soluble functional variants of therapeutic
proteins is a challenging task, usually addressed using com-
binatorial experimental approaches, such us phage display
(31). A goal of any aggregation prediction algorithm is to
provide a routine that can substitute for these experiments,
saving time and costs. Ideally, this routine should be simple
enough to be accessible to non-expert users. With these two
objectives in mind, we implemented the ‘automated muta-
tions’ tool in A3D 2.0, accessible at the server front page
through the ‘Enhance protein solubility’ option.
The ‘automated mutations’ tool identifies the most
aggregation-prone patches at the protein surface and vir-
tually mutates their residues by charged amino acids, under
the assumption that they would act as ‘gatekeepers’, coun-
teracting protein self-association. Then it provides a ranked
list of point mutations, where both the solubilizing and en-
ergetic effects are taken into account, in such a way that the
user can discard potentially solubilizing, but destabilizing
mutations.
The optimization of the solubility of antibodies is espe-
cially difficult, because, in these molecules, the tight binding
to their targets depends on the presence of exposed APRs at
their complementarity-determining regions (CDRs). This is
the reason why computer- (32) or experiment- (33) based de-
signs usually target residues within or close to CDRs; how-
ever, these changes might compromise significantly the an-
tibody affinity. A3D 2.0 addresses this problem by allow-
ing users to exclude from the virtual screening functionally
relevant residues, i.e. CDRs in antibodies or active sites in
enzymes.
The ‘automated mutation’ tool has been used for the re-
design of an aggregation-prone Variable Heavy (VH) seg-
ment of the human antibody germline (34). Soluble vari-
ants of this antibody were previously evolved by phage dis-
play, but all the introduced mutations clustered at one of
the CDRs (35). A3D 2.0 was ran pre-excluding residues
at the CDRs. Mutations at three different residues outside
these domains were automatically suggested (Figure 4A).
A designed VH variant containing the 3 top ranked muta-
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Figure 2. Aggregation propensity for different multimeric proteins, calculated in static or dynamic modes. (A) The aggregation propensity of the static
input structure relative to that of the 12 dynamic models is represented for homodimers, heterodimers, antibodies or the complete set. In the color scale,
dark blue indicates the static structure being the most soluble (ranking 1) and dark red the static structure being the most aggregation-prone (ranking 13).
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Figure 3. A3D 2.0 as a tool for the in silico redesign of more stable and soluble proteins. A3D structures of original GFP (left) (PDB: 2B3Q:A) and
engineered GFP/KKK mutant (right) (PDB: 6FWW) coloured according to the A3D score. Mutations lowering aggregation propensity, while maintaining
protein stability are encircled. The mutated variant was experimentally shown to be 2-fold more resistant against aggregation (19).
ure 4B), turning to be significantly more resistant against
aggregation than the original germline antibody (19).
DESCRIPTION OF THE WEB SERVER
Input interface and requirements
The only required input is a protein structure in PDB for-
mat (given as a PDB code or uploaded by user in the ‘In-
put structure’ panel). Optionally, a user can provide desired
chain(s) identifier(s) (only provided chains will be used in
the A3D analysis). In the ‘Options’ panel, there are several
additional options to be chosen:
• Project name––the name under which the project will be
displayed (and which can be used to find it via the project
name search on the top of the page)
• Email address––provided an email address the server will
notify the user when the job has started and ended
• Stability calculations––if selected (default: Yes), the sub-
mitted structure will be energetically minimized before
the A3D analysis using FoldX and stability calculated in
case mutations are defined.
• Dynamic mode––in this mode, the input structure’s flex-
ibility will be simulated using the CABS-flex software. A
set of predicted models reflecting the flexibility of the in-
put structure will be analysed and scored for aggregation
propensity. Note: this option cannot be used with the ‘En-
hance protein solubility’ option.
• Mutate residues––if selected, the option allows a user to
select residues and perform point mutations on the input
structure, which are built using FoldX. Selecting this op-
tion will prompt a new window, which allows introducing
the desired mutation(s). Note: this option cannot be used
with the ‘Enhance protein solubility’ option.
• Distance of aggregation analysis––in the A3D method,
the intrinsic aggregation propensity of each particular
amino acid in the structure is modulated by its specific
structural context. Aggregation propensity is calculated
for spherical regions centered on every residue C car-
bon. This option allows changing the size of said region
allowing for more and less granular approaches.
• Enhance protein solubility––Please see Methods for de-
tails on the automated mutations workflow behind this
option. Selecting it will prompt a new window to open
upon submitting, where the user can prevent chosen
residues from being mutated. Note: This option cannot
be used with ‘Mutate residues’ or ‘Dynamic mode’ op-
tions.
• Do not show my job in the results page - if the box is
ticked the job will not be visible to other A3D 2.0 users.
For more details, see the online documentation available
from the ‘Tutorial’ tab.
Output interface
For each submitted job, the output interface is organized
under the following tabs: ‘Project details’, ‘Aggrescan3D
plot’, ‘Aggrescan3D score’, ‘Structure’, ‘Automated muta-
tions’ (available only if the job was submitted with the op-
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Figure 4. Automated mutations for variable heavy (VH) segment of a human germline antibody. (A) A3D 2.0 automated mutations output (the residues
at the three antibody CDRs were excluded from the screening). (B) The blue highlighted mutations in panel A were combined to render triple mutant
engineered antibody. Structures of wild type (PDB: 5I19) and the mutant, as predicted by A3D 2.0. Solubilizing mutations are encircled. The engineered
antibody variant was experimentally shown to be 3-fold more resistant against aggregation (19).
(available only if the job was submitted in the ‘Dynamic
mode’) and ‘Gallery’. The content of these tabs is pre-
sented and described in the online documentation. Here, we
present only short descriptions:
• ‘Project details’ tab––contains information about the
specified options used to run the job and links to down-
load the job data. It also provides stability calculations,
when it applies.
• ‘Aggrescan3D plot’ tab––presents A3D analysis results in
the form of an interactive online plot for a selected pro-
tein chain.
• ‘Aggrescan3D score’ tab––presents A3D analysis results
in the form of an interactive table together with ‘mutate’
buttons in the right side of the table, which allows to re-
submit the job with chosen mutations.
• ‘Structure’ tab––allows viewing an analysed structure in
an interactive way. The residues are colored in shades
from dark blue (high soluble residues), through white (no
predicted influence on aggregation properties), to dark
red (aggregation prone residues). Various visualization
options are possible.
• ‘Dynamic mode details’ tab––presents A3D analysis re-
sults for a set of models reflecting flexibility of the input
structure. The results are organized in the table and inter-
active plots presenting scores for particular models.
• ‘Automated mutations’ tab––presents A3D analysis re-
sults for a set of mutant models generated using option
‘Enhance protein solubility’. The results are organized in
the table and interactive plots presenting scores for par-
ticular protein variants.
• ‘Gallery’ tab - contains all screenshots taken by users (us-








300/5485072 by guest on 10 June 2020
W306 Nucleic Acids Research, 2019, Vol. 47, Web Server issue
Online documentation
The documentation can be found on the server itself un-
der the ‘Tutorial’ tab (available from the main menu). Ad-
ditionally, the web interface provides short help notes that
are available close to the presented content. The online doc-
umentation is updated on a regular basis according to users’
needs or the server improvement.
Command-line availability
The A3D 2.0 server can be also operated from the command
line using RESTful web services. The instructions for using
the RESTful service are available from the online tutorial
(accessible from the main menu).
Server architecture
The Aggrescan3D 2.0 server is a HTML based service dy-
namically generated using the Flask framework and the
jinja2 templating engine. The user data is stored using a
MySQL database upon submission and unique id and a sta-
tus are assigned for each job. The server notifies the user
of its progress by a job status, which is ‘pending’ when
the server is waiting for a computational cluster response,
‘queue’ when there are no resources available yet, ‘running’
and then finally either ‘done’ or ‘error’. The simulation
is carried out using the Aggrescan3D standalone software
(that is available at http://bitbucket.org/lcbio/aggrescan3d)
and other previously described programs (with the RSA cal-
culations done by FreeSASA software (36)). The structures
are presented in an interactive way using the 3Dmol library
(HTML5/Javascript). The A3D score plot is done using the
D3.js library (HTML5/Javascript) and the model and mu-
tant comparison plots are generated using the Bokeh library
(Python/Javascript). The PDB structures are obtained us-
ing RESTful services. The A3D 2.0 website handles user’s
requests using an Apache2 server. The A3D 2.0 server is
free, open to all users and there is no login requirement.
SUMMARY
In this work, we developed an easy-to-use A3D 2.0 web
server interface for the prediction and engineering of pro-
tein solubility. The implemented changes boost the server
functionality with an unprecedented combination of fea-
tures for APRs identification and design taking into ac-
count dynamic and thermodynamic aspects in the predic-
tions. A3D 2.0 can find application in the identification and
analysis of pathogenic familial mutations in conformational
disorders, but, it is specially intended to assist the design of
soluble proteins for biotechnological and biomedical appli-
cations, where it should contribute to reduce development
costs and times.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
FUNDING
Spanish Ministry of Economy and Competitiveness
[BIO2016-78310-R to S.V., ICREA, ICREA-Academia
2015 to S.V.]; National Science Center (NCN, Poland)
Grant [MAESTRO2014/14/A/ST6/00088 to M.K and
S.K.].
Conflict of interest statement. None declared.
REFERENCES
1. Chiti,F. and Dobson,C.M. (2017) Protein misfolding, amyloid
formation, and human disease: a summary of progress over the last
decade. Annu. Rev. Biochem., 86, 27–68.
2. Invernizzi,G., Papaleo,E., Sabate,R. and Ventura,S. (2012) Protein
aggregation: mechanisms and functional consequences. Int. J.
Biochem. Cell Biol., 44, 1541–1554.
3. Hamrang,Z., Rattray,N.J. and Pluen,A. (2013) Proteins behaving
badly: emerging technologies in profiling biopharmaceutical
aggregation. Trends Biotechnol., 31, 448–458.
4. Pallares,I. and Ventura,S. (2017) Advances in the prediction of
protein aggregation propensity. Curr. Med. Chem.,
doi:10.2174/0929867324666170705121754.
5. Meric,G., Robinson,A.S. and Roberts,C.J. (2017) Driving forces for
nonnative protein aggregation and approaches to predict
Aggregation-Prone regions. Annu. Rev. Chem. Biomol. Eng., 8,
139–159.
6. Ricardo Graña-Montes,J.P.-P., Carlota,Gómez-Picanyol and
Ventura,A.S. (2017) In: Rigden,DJ (ed). From Protein Structure to
Function with Bioinformatics. Springer, pp. 205–263.
7. Zambrano,R., Jamroz,M., Szczasiuk,A., Pujols,J., Kmiecik,S. and
Ventura,S. (2015) AGGRESCAN3D (A3D): server for prediction of
aggregation properties of protein structures. Nucleic Acids Res., 43,
W306–W313.
8. Pujols,J., Pena-Diaz,S. and Ventura,S. (2018) AGGRESCAN3D:
Toward the prediction of the aggregation propensities of protein
structures. Methods Mol. Biol., 1762, 427–443.
9. Conchillo-Sole,O., de Groot,N.S., Aviles,F.X., Vendrell,J., Daura,X.
and Ventura,S. (2007) AGGRESCAN: a server for the prediction and
evaluation of “hot spots” of aggregation in polypeptides. BMC
Bioinformatics, 8, 65.
10. de Groot,N.S., Castillo,V., Grana-Montes,R. and Ventura,S. (2012)
AGGRESCAN: method, application, and perspectives for drug
design. Methods Mol. Biol., 819, 199–220.
11. Jamroz,M., Kolinski,A. and Kmiecik,S. (2013) CABS-flex: server for
fast simulation of protein structure fluctuations. Nucleic Acids Res.,
41, W427–W431.
12. Kuriata,A., Gierut,A.M., Oleniecki,T., Ciemny,M.P., Kolinski,A.,
Kurcinski,M. and Kmiecik,S. (2018) CABS-flex 2.0: a web server for
fast simulations of flexibility of protein structures. Nucleic Acids Res.,
46, W338–W343.
13. Pulido,P., Llamas,E., Llorente,B., Ventura,S., Wright,L.P. and
Rodriguez-Concepcion,M. (2016) Specific Hsp100 chaperones
determine the fate of the first enzyme of the plastidial isoprenoid
pathway for either refolding or degradation by the stromal Clp
protease in arabidopsis. PLos Genet., 12, e1005824.
14. Pulido,D., Arranz-Trullen,J., Prats-Ejarque,G., Velazquez,D.,
Torrent,M., Moussaoui,M. and Boix,E. (2016) Insights into the
antimicrobial mechanism of action of human RNase6: structural
determinants for bacterial cell agglutination and membrane
permeation. Int. J. Mol. Sci., 17, 552.
15. Soler,M.A., de Marco,A. and Fortuna,S. (2016) Molecular dynamics
simulations and docking enable to explore the biophysical factors
controlling the yields of engineered nanobodies. Sci. Rep., 6, 34869.
16. Bhandare,V.V. and Ramaswamy,A. (2018) The proteinopathy of
D169G and K263E mutants at the RNA Recognition Motif (RRM)
domain of tar DNA-binding protein (tdp43) causing neurological
disorders: a computational study. J. Biomol. Struct. Dyn., 36,
1075–1093.
17. Zerovnik,E. (2017) Putative alternative functions of human stefin B
(cystatin B): binding to amyloid-beta, membranes, and copper. J.
Mol. Recognit., 30, e2562.
18. Katina,N.S., Balobanov,V.A., Ilyina,N.B., Vasiliev,V.D.,
Marchenkov,V.V., Glukhov,A.S., Nikulin,A.D. and Bychkova,V.E.
(2017) sw ApoMb amyloid aggregation under nondenaturing









300/5485072 by guest on 10 June 2020
Nucleic Acids Research, 2019, Vol. 47, Web Server issue W307
19. Gil-Garcia,M., Bano-Polo,M., Varejao,N., Jamroz,M., Kuriata,A.,
Diaz Caballero,M., Lascorz,J., Morel,B., Navarro,S., Reverter,D.
et al. (2018) Combining structural aggregation propensity and
stability predictions to re-design protein solubility. Mol. Pharm., 15,
3846–3859.
20. Xia,X., Kumru,O.S., Blaber,S.I., Middaugh,C.R., Li,L., Ornitz,D.M.,
Sutherland,M.A., Tenorio,C.A. and Blaber,M. (2016) Engineering a
cysteine-free form of human fibroblast growth Factor-1 for “Second
Generation” therapeutic application. J. Pharm. Sci., 105, 1444–1453.
21. Kurcinski,M., Oleniecki,T., Ciemny,M.P., Kuriata,A., Kolinski,A.
and Kmiecik,S. (2019) CABS-flex standalone: a simulation
environment for fast modeling of protein flexibility. Bioinformatics,
35, 694–695.
22. Schymkowitz,J., Borg,J., Stricher,F., Nys,R., Rousseau,F. and
Serrano,L. (2005) The FoldX web server: an online force field. Nucleic
Acids Res., 33, W382–W388.
23. Jamroz,M., Kolinski,A. and Kmiecik,S. (2014) CABS-flex predictions
of protein flexibility compared with NMR ensembles. Bioinformatics,
30, 2150–2154.
24. Jamroz,M., Orozco,M., Kolinski,A. and Kmiecik,S. (2013)
Consistent view of protein fluctuations from all-atom molecular
dynamics and coarse-grained dynamics with knowledge-based
force-field. J. Chem. Theory Comput., 9, 119–125.
25. Gridelli,C., de Castro Carpeno,J., Dingemans,A.C., Griesinger,F.,
Grossi,F., Langer,C., Ohe,Y., Syrigos,K., Thatcher,N., Das-Gupta,A.
et al. (2018) Safety and efficacy of bevacizumab plus
Standard-of-Care treatment beyond disease progression in patients
with advanced non-small cell lung cancer: the AvaALL randomized
clinical trial. JAMA Oncol., 4, e183486.
26. Oliva,A., Llabres,M. and Farina,J.B. (2014) Capability measurement
of size-exclusion chromatography with a light-scattering detection
method in a stability study of bevacizumab using the process
capability indices. J. Chromatogr. A., 1353, 89–98.
27. Courtois,F., Agrawal,N.J., Lauer,T.M. and Trout,B.L. (2016)
Rational design of therapeutic mAbs against aggregation through
protein engineering and incorporation of glycosylation motifs applied
to bevacizumab. mAbs, 8, 99–112.
28. Espargaro,A., Castillo,V., de Groot,N.S. and Ventura,S. (2008) The in
vivo and in vitro aggregation properties of globular proteins correlate
with their conformational stability: the SH3 case. J. Mol. Biol., 378,
1116–1131.
29. Castillo,V., Espargaro,A., Gordo,V., Vendrell,J. and Ventura,S. (2010)
Deciphering the role of the thermodynamic and kinetic stabilities of
SH3 domains on their aggregation inside bacteria. Proteomics, 10,
4172–4185.
30. Franzosa,E.A. and Xia,Y. (2009) Structural determinants of protein
evolution are context-sensitive at the residue level. Mol. Biol. Evol.,
26, 2387–2395.
31. Sidhu,S.S. (2000) Phage display in pharmaceutical biotechnology.
Curr. Opin. Biotechnol., 11, 610–616.
32. Sormanni,P., Aprile,F.A. and Vendruscolo,M. (2015) The CamSol
method of rational design of protein mutants with enhanced
solubility. J. Mol. Biol., 427, 478–490.
33. Perchiacca,J.M., Lee,C.C. and Tessier,P.M. (2014) Optimal charged
mutations in the complementarity-determining regions that prevent
domain antibody aggregation are dependent on the antibody scaffold.
Protein Eng. Des. Sel., 27, 29–39.
34. Teplyakov,A., Obmolova,G., Malia,T.J., Luo,J., Muzammil,S.,
Sweet,R., Almagro,J.C. and Gilliland,G.L. (2016) Structural diversity
in a human antibody germline library. mAbs, 8, 1045–1063.
35. Dudgeon,K., Rouet,R., Kokmeijer,I., Schofield,P., Stolp,J.,
Langley,D., Stock,D. and Christ,D. (2012) General strategy for the
generation of human antibody variable domains with increased
aggregation resistance. Proc. Natl. Acad. Sci. U.S.A., 109,
10879–10884.
36. Mitternacht,S. (2016) FreeSASA: an open source C library for
solvent accessible surface area calculations [version 1; peer review: 2








300/5485072 by guest on 10 June 2020
